Sign in
Taking peoplePhase 4

Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

Key facts

Who runs it
Piotr Czempik
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
10 Nov 2024
Expected to end
1 Apr 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Iron
  • EPO
  • 0.9 % NaCl
Record updated
27 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • age ≥18,
  • diagnosed sepsis (Sepsis-3) or septic shock (Septic Shock-3),
  • hemoglobin <120 g/L in both sexes

Who cannot take part

  • bleeding,
  • decompensated liver disease,
  • inherited microcytic disorders,
  • allergy to epoetin alfa and/or iron derisomaltose,
  • macrocytosis,
  • contraindications to pharmacological prophylaxis of VTE,
  • pregnancy,
  • ferritin concentration >800 ng/mL,
  • unable to take informed consent

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Anemia or sepsis or septic shock

This trial is currently available in Poland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background Up to 66% of have anemia at the admission to the intensive care unit. This number increases to 95% after 72 hours of hospitalization in the intensive care unit due to illness and iatrogenic blood loss. Anemia worsens tissue oxygenation, especially in patietns with sepsis or septic shock, who already have blood flow issues. Instead of giving blood transfusions, which can have side effects, we aim to address the root causes of anemia in these patients. Sepsis can cause "inflammatory anemia" and combine with iron deficiency anemia. Current anemia treatments include drugs that stimulate red blood cell production and intravenous iron supplements. Some think that iron supplements can worsen infections by feeding pathogens, but this is not conclusively proven. Since transfused red blood cells (RBC) also contain iron, small doses of intravenous iron might help sepsis patients with iron deficiency.

Read full original descriptionShow less

There is a need for a study on the effects of epoetin alfa and iron derisomaltose on hemoglobin (Hb) levels in sepsis patients.

Hypothesis and Aim Treating anemia in sepsis patients could increase Hb levels and reduce RBC transfusions, improving patient outcomes. This study aims to evaluate the effects of epoetin alfa ± iron derisomaltose on Hb levels and RBC transfusion rates.

Primary Endpoints:

1. Hb difference at study exit (discharge from ICU/death/bleeding/need for surgery/day 15 whatever comes first) and day 1 corrected for Hb increase due to possible RBC transfusion

Secondary Endpoints:

1. Hb difference on days 8 and 1 corrected for Hb increase due to possible RBC transfusion 2. Hb difference on days 15 and 1 corrected for Hb increase due to possible RBC transfusion 3. number of blood transfusions 4. percentage of patients receiving at least one blood transfusion 5. actual vs. predicted mortality 6. prevalence of deep vein thrombosis and pulmonary embolism 7. mortality rates in ICU, hospital, 30-day, and 90-day.

Materials and Methods:

This will be a randomized controlled clinical trial recruting 200 patients

Inclusion Criteria:

1. age ≥18 2. diagnosed sepsis (Sepsis-3 definition) or septic shock (Septic Shock-3 definition) 3. hemoglobin <120 g/L for both sexes

Exclusion Criteria:

1. bleeding 2. decompensated liver disease 3. inherited microcytic disorders 4. macrocytosis 5. contraindications to pharmacological prophylaxis for venous thromboembolism 6. pregnancy 7. allergy to epoetin alfa and/or iron derisomaltose. 8. ferritin >800 ng/mL. 9. inability to take consent

Study Group:

1. epoetin alfa 50 u/kg IV (days 1, 3, 5, 8, 10, 12) 2. iron derisomaltose 0.2g IV when RET-He <29.3 pg (days 1, 3, 5, 8, 10, 12) 3. algorithm for red blood cell transfusions

Control Group:

1. algorithm for red blood cell transfusions

Laboratory Parameters:

Initial: interleukin-6, procalcitonin, C-reactive protein, creatinine, ammonia, blood urea nitrogen, aspartate aminotransferase, alanine aminotransferase, total bilirubin, complete blood count (CBC), reticulocytes (RET), ferritin, iron, transferrin.

Serial: CBC and RET (days 1, 3, 5, 8, 10, 12)

The 2 groups in the trial

  • Epoetin alfa +/- ferric derisomaltoseTreatment being tested

    Epoetin alfa 50 units/kg IV 3 times weekly and ferric derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg

    Treatment: Iron and EPO

  • PlaceboPlacebo, for comparison

    0.9% NaCl

    Treatment: 0.9 % NaCl

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Use of Epoetin Alfa and Iron Derisomaltose in the Treatment of Anemia in Patients With Sepsis or Septic Shock Hospitalized in the Intensive Care Unit: a Randomized Controlled Clinical Trial
Criteria questions
Built from NCT06670963, who can take part
Record updated
27 December 2024